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maps of the SC and classic FEF 
are different, and only few FEF cells 
encode ipsilateral saccades [8] (with 
an unknown motor map). Possible 
further support for this argument is 
that SE had spared FEFs and weak 
probe effects. 
A brief current pulse to the 
superfi cial layer of the rat SC 
produces a prolonged (~300 ms) 
burst of excitatory postsynaptic 
current in intermediate layer cells 
[10]. An additional input to the deeper 
layers could trigger a saccade. By 
extension, a visual stimulus in the 
blind hemifi eld of our patients could 
not, on its own, trigger a goal-directed 
saccade, presumably because motor 
activity in the intermediate layers of 
the ipsilesional SC (SCi) is absent. 
Thus, we hypothesize, mostly for 
DR, that probe-evoked activity in 
retino-tectal afferents to the SCi’s 
superfi cial layers descended to 
intermediate layers and enhanced 
weak motor preparatory activity for 
contralesional anti-saccades, itself 
due to a crossed descending motor 
signal from contralesional FEF-to-SCi 
[4,8]. The many and varied residual 
abilities among blindsight patients 
suggest that blindsight relies on more 
than one residual pathway. Here 
we provide evidence indicating that 
the mammalian homologue of the 
primitive reptilian retino-tecto-reticular 
pathway is remarkably functional in 
humans, thus permitting a form of 
‘action’ blindsight [1].
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Neuroscience research in non-human 
primates (NHPs) has delivered 
fundamental knowledge about 
human brain function as well as 
some valuable therapies that have 
improved the lives of human patients 
with a variety of brain disorders. 
Research using NHPs, although 
it is facing serious challenges, 
continues to complement studies in 
human volunteers and patients, and 
will continue to be needed as the 
burdens of mental health problems 
and neurodegenerative diseases 
increase. At the same time, research 
into the 3Rs is helping to ameliorate 
the harms experienced by NHPs in 
experimental procedures, allowing 
the effective combination of optimal 
welfare conditions for the NHPs and 
high quality research.  
We write as a group of UK 
scientists committed to neuroscience 
research in NHPs at a critical point in 
the debate over their use in research. 
Our commitment stems from the 
notable advances that this research 
has already achieved, and because 
of our awareness that the monkey 
represents the best available model 
for our understanding of the human 
brain. Last year, the EU SCHEER 
report [1] highlighted key research 
areas where NHPs were still needed. 
These included testing of new drugs, 
infectious diseases (including Ebola, 
Zika and TB), and neuroscience. 
The need to alleviate the modern 
burdens of human neurodegenerative 
diseases and mental health 
disorders represents one of the most 
powerful arguments for sustaining 
primate research. This research 
now engages modern molecular, 
electrophysiological, behavioural and 
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underlying mechanisms of disease, 
and some of it will lead to successful 
treatments.
We emphasise that NHP studies, 
using invasive methods, complement 
those in human volunteers and 
patients, using non-invasive 
methods such as brain imaging 
and computational modelling. For 
example, the Brain Prize in 2017 was 
awarded to three scientists in the 
UK who, respectively, discovered 
the neuronal mechanism of reward 
in monkeys, modelled this reward 
mechanism, and tested these models 
in human volunteers using fMRI [2]. 
Recent analysis shows that scientists 
who use NHPs in their research are 
also very active in using non-animal 
approaches to address current 
problems in basic and translational 
neuroscience [3]. NHP scientists also 
contribute to advances in welfare and 
the 3Rs [3].
Similarly, close interaction between 
human and monkey studies was 
also vital to the development of the 
parkinsonian model in the macaque 
which led to the discovery that 
deep brain stimulation of a tiny 
brain structure, the subthalamic 
nucleus, was an effective therapy 
for the motor disorders associated 
with Parkinson’s disease, research 
that was recognised by the Lasker 
Award in 2014  [4]. Over 250,000 
Parkinson patients worldwide have 
since benefi ted from this treatment. 
Recent developments that have come 
directly from monkey research include 
the use of brain–machine interfaces 
for restoring movement to paralysed 
patients, new therapies for stroke 
patients with poor hand function, new 
strategies to harness brain plasticity 
to compensate for perceptual 
and cognitive impairment, and a 
better understanding of symptoms 
underlying psychiatric disorders as 
well as cognitive functioning in the 
healthy brain. 
UK and EU animal research 
legislation requires a ‘harm–benefi t’ 
analysis to determine whether the 
harms involved in the research are 
justifi ed by advances in fundamental 
science or medical benefi ts that might 
result from the study. Therefore, in 
addition to assessing the benefi ts 
of NHP research, there has been an increased focus on reducing 
harms and understanding the overall 
level of severity experienced by 
research animals. This is of particular 
signifi cance for NHPs in long-term 
neuroscience studies involving 
complex behavioural tasks. 
Government regulators in the UK, 
and in some other EU countries, 
prospectively assess all such research 
as ‘severe’ because of the potential 
to cause severe harm. Critically, 
accumulating evidence shows that the 
lifetime experience of a great majority 
of the monkeys used in academic 
research in the UK is not severe, but 
is actually ‘moderate’. Starting in 
2013, annual retrospective reviews 
of the actual severity experienced 
by each monkey in neuroscience 
research procedures has revealed that 
only 1% of the 366 monkeys used 
(New World marmosets and Old World 
macaques) actually experienced 
severe harms (as defi ned by the EU 
Directive 2013/63/), while most (66%) 
experienced moderate harms, or less 
(26% ‘mild’ and 7% ‘non-recovery’). 
These results are consistent with the 
broader set of United Kingdom Home 
Offi ce statistics for basic research 
using NHPs over the same period 
(3% of severe procedures for the 
years 2013–2016). They also confi rm 
the moderate level of harms that was 
fi rst reported by the Home Offi ce 
Pickard Report in 2013 [5]. This key 
distinction between the potential to 
cause severe harm and the actual 
level of severity is crucial but is often 
lost or misunderstood in discussions 
amongst the general public.
We are seriously concerned 
about calls to UK and other EU 
government regulators for a ban on 
all research involving NHPs, as well 
as in many other species, which 
has a prospective rating of severe. 
Such a ban would prevent disease-
related medical and neuroscience 
research, damaging both fundamental 
and translational science. We have 
identifi ed two serious consequences 
that such a ban would cause to NHP 
neuroscientifi c research; many more 
exist and will develop, impacting 
the wider scientifi c community, the 
welfare of non-human species, and 
human health. 
First, it would ban most of the 
basic, fundamental neuroscience Current Biology 2research, essential for understanding 
complex cognition and other 
processes that occur in the primate 
brain. We stress that the ban would 
result from the current situation 
in which most NHP neuroscience 
research is currently prospectively 
banded severe by government 
regulators, although as pointed out 
above, the great majority of primates 
used actually experience moderate 
harms or less. 
Second, it would ban any present 
(or future) study in which a disease 
model is created in a monkey, 
indeed necessarily causing severe 
harms that refl ect the impact of the 
brain disorder (e.g. Parkinson’s)  in 
humans.  But limited use of such 
models is still essential to help fi nd 
effective treatments for a whole 
range of neurodegenerative and 
neuropsychiatric conditions that affect 
millions of humans. 
We believe that in the coming 
period some increase in NHP 
studies in carefully targeted areas of 
neuroscience will still be needed. To 
ban useful primate disease models 
would be an extremely dangerous 
step to take, given the urgent need to 
fi nd treatments for people suffering 
from these conditions. 
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